Astria Therapeutics, Inc. ( (ATXS) ) has released its Q3 earnings. Here is a breakdown of the information Astria Therapeutics, Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Astria Therapeutics, Inc. is a biopharmaceutical company dedicated to developing transformative therapies for allergic and immunologic diseases, with a focus on hereditary angioedema and atopic dermatitis. In its third quarter 2025 financial report, Astria Therapeutics announced its acquisition by BioCryst Pharmaceuticals, expected to finalize in early 2026, alongside updates on its key drug development programs. The company highlighted significant progress in its clinical trials, particularly with navenibart, which showed promising results in reducing attack rates in hereditary angioedema patients. Additionally, Astria’s STAR-0310 program demonstrated potential as a leading treatment for atopic dermatitis. Financially, Astria reported a net loss of $31.6 million for the quarter, with increased research and development expenses attributed to ongoing clinical trials. Looking ahead, Astria remains optimistic about its strategic direction and continued advancements in its drug development pipeline, supported by the upcoming merger with BioCryst.